28 March 2019
Time: 17:00-18:30 CET
REVIVE is an online space to connect and support the antimicrobial R&D community. REVIVE’s aims are to facilitate learning, connect people, and share knowledge. The REVIVE webinar series on antimicrobial drug discovery and R&D is brought to you by GARDP’s Antimicrobial Memory Recovery & Exploratory Programme.
REVIVE Webinar Series
Antibacterial drugs: Clinical development for non-developers
Part 3: Development of antibacterial drug enhancer combinations and non-traditional products
Moderator: David Shlaes, Anti-Infectives consulting, retired
- Ian Friedland, Clinical consultant, Friedland Strategic Consulting, LLC
- Sumathi Nambiar, Director, Division of Anti-Infective Products, Office of Antimicrobial Products, CDER, FDA
- Mair Powell, Senior Clinical Assessor, Health Products Regulatory Authority, Ireland
The overall goal of this series of webinars is to provide, for the non-clinical developer, an understanding of the risks of development for various kinds of antibacterial products. Our first webinar was devoted to more traditional approaches (Tiers A and B), best suited for more broad-spectrum products, where the risks are lower. In the second webinar, we discussed the development of products that target a single species of bacteria where the risks may be higher. In this third webinar, we will discuss the development of antibacterial drug enhancer combinations and non-traditional products.
|Register here for this live webinar including interactive Q&A session on 28 March 2019, 17:00-18:30 (CET).|
If you have questions or comments, please let us know. Do so by using the ‘question’ pane on the webinar control panel during the live webinar or send your questions beforehand or afterwards to: email@example.com.